4th Immport Ontology Group Web Conference: Difference between revisions
From NCOR Wiki
Jump to navigationJump to search
mNo edit summary |
m (→Next Steps) |
||
(12 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
'''Draft Schedule''' | '''Draft Schedule''' | ||
4:00pm (EST) | 4:00pm (EST) Discussion of CyTOF / PRO / CL workflow | ||
== CyTOF –CL workflow == | |||
Alan Ruttenberg - https://bisc2012.atlassian.net/browse/OD-48 | |||
'''Protocol for classifying and recording cell type/populations from CYTOF experiments''' | |||
* Review proposed inputs | |||
** Is information gathered adequate? | |||
** Are offering choices for input useful? | |||
* Splitting out into separate workflows | |||
** Registering/curating an antibody | |||
** Assigning qualitative marker levels | |||
** Clustering/gating | |||
* Understanding the SPARQL query | |||
* The review step | |||
* Identifying a data set for validating the workflow. - | |||
** Is Bendall et al., 332 (6030): 687-696 a good source? Review. | |||
** Arranging time with someone on Nolan team to prepare this set | |||
== Protein Ontology (PRO) == | |||
* How to use the PRO (Alex Diehl) | |||
* Curating protein complexes | |||
== Cell Ontology (CL) == | |||
'''Adding markers to CL classes so that they can be computed on (instead of having them as comments)''' | |||
Alex Diehl, Alan Ruttenberg | |||
* https://bisc2012.atlassian.net/browse/ID-205 | |||
** Difference between initial spreadsheets and Dougall's | |||
** Asserting that a surface marker appears on every instance of annotated-to cell type | |||
** Asserting capability of secreting cytokine on every instance of annotated-to cell type | |||
** Ignoring other types (e.g. transcription factors) for now | |||
* https://bisc2012.atlassian.net/browse/OD-28 | |||
** Discussion of where different types of information go | |||
*** Distinguish CL from CL-Provisional (resource to support Immport experimental work which extends CL)? | |||
*** Antibodies used to detect cell type in different experimental paradigms | |||
*** Extrinsic experimental properties such as side-scatter | |||
== Immport Antibody Registry == | |||
Alex Diehl | |||
* What is planned/should be recorded | |||
* How to host work in progress (triple store?) | |||
* Do we need indications of status of curation? | |||
* What to expect when | |||
* Process for Identifying new antibodies to be included in registry | |||
== Next Steps == | |||
Barry Smith and Yannick Pouliot | |||
*General issue of cell type versus cell state (why 'mature cell' is not a type of cell) | |||
6:00pm (EST) Close | |||
Note that the originally planned discussion of [[HIPC Standards and Ontologies]] has been postponed, due to urgency of this workflow issue. |
Latest revision as of 12:30, 24 June 2013
Draft Schedule
4:00pm (EST) Discussion of CyTOF / PRO / CL workflow
CyTOF –CL workflow
Alan Ruttenberg - https://bisc2012.atlassian.net/browse/OD-48
Protocol for classifying and recording cell type/populations from CYTOF experiments
- Review proposed inputs
- Is information gathered adequate?
- Are offering choices for input useful?
- Splitting out into separate workflows
- Registering/curating an antibody
- Assigning qualitative marker levels
- Clustering/gating
- Understanding the SPARQL query
- The review step
- Identifying a data set for validating the workflow. -
- Is Bendall et al., 332 (6030): 687-696 a good source? Review.
- Arranging time with someone on Nolan team to prepare this set
Protein Ontology (PRO)
- How to use the PRO (Alex Diehl)
- Curating protein complexes
Cell Ontology (CL)
Adding markers to CL classes so that they can be computed on (instead of having them as comments) Alex Diehl, Alan Ruttenberg
- https://bisc2012.atlassian.net/browse/ID-205
- Difference between initial spreadsheets and Dougall's
- Asserting that a surface marker appears on every instance of annotated-to cell type
- Asserting capability of secreting cytokine on every instance of annotated-to cell type
- Ignoring other types (e.g. transcription factors) for now
- https://bisc2012.atlassian.net/browse/OD-28
- Discussion of where different types of information go
- Distinguish CL from CL-Provisional (resource to support Immport experimental work which extends CL)?
- Antibodies used to detect cell type in different experimental paradigms
- Extrinsic experimental properties such as side-scatter
- Discussion of where different types of information go
Immport Antibody Registry
Alex Diehl
- What is planned/should be recorded
- How to host work in progress (triple store?)
- Do we need indications of status of curation?
- What to expect when
- Process for Identifying new antibodies to be included in registry
Next Steps
Barry Smith and Yannick Pouliot
- General issue of cell type versus cell state (why 'mature cell' is not a type of cell)
6:00pm (EST) Close
Note that the originally planned discussion of HIPC Standards and Ontologies has been postponed, due to urgency of this workflow issue.